Results 41 to 50 of about 69,283 (286)
Clinics, 2014 With advancing age, there is an increase in the complaints of a lack of a libido in women and erectile dysfunction in men. The efficacy of phosphodiesterase type 5 inhibitors, together with their minimal side effects and ease of administration ...
Sandra Léa Bonfim Reis +1 more
doaj +1 more source
Food supplements adulteration with undeclared synthetic phosphodiesterase type-5 drugs (PDE-5) inhibitors [PDF]
, 2014 The use ofplant food supplements (PFS) in developed countries is becoming increasingly popular mostly due to the consumers' widespread idea that natural products are safer and healthier than conventional pharmaceutical drugs [l].
Amaral, Joana S. +2 more
core +1 more source
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization [PDF]
, 2017 PURPOSE: Phosphodiesterase type-5 inhibitor administration in diabetic men with erectile dysfunction (ED) is associated with reduced waist circumference.
Aversa, Antonio +8 more
core +1 more source
Phosphodiesterase Type 5 Inhibitor Use and Hearing Impairment [PDF]
Archives of Otolaryngology–Head & Neck Surgery, 2010 To compare use of phosphodiesterase type 5 inhibitors (PDE-5i) between participants with and without self-reported hearing impairment using logistic regression, with and without adjustment for potentially confounding sociodemographic, behavioral, and health-related characteristics.Cross-sectional.United States.A population-based sample of 11 525 men 40
openaire +2 more sources
Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan
Urological Science, 2016 Erectile dysfunction (ED) is a prevalent form of male sexual dysfunction. Phosphodiesterase type 5 (PDE5) inhibitor is the first-line treatment for ED. Numerous well-designed and -conducted clinical trials and postmarketing studies have established the ...
Bang-Ping Jiann
doaj +1 more source
Cyclic AMP signalling in pancreatic islets [PDF]
, 2010 Cyclic 3'5'AMP (cAMP) is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet β-cell, where it is formed by the activity of adenylyl cyclases, which are stimulated by glucose, through elevation in ...
Furman, Brian +2 more
core +1 more source
cAMP-Inhibits Cytoplasmic Phospholipase A(2) and Protects Neurons against Amyloid-beta-Induced Synapse Damage [PDF]
, 2015 A key event in Alzheimer’s disease (AD) is the production of amyloid-β (Aβ) peptides and the loss of synapses. In cultured neurons Aβ triggered synapse damage as measured by the loss of synaptic proteins. α-synuclein (αSN), aggregates of which accumulate
Bate, C, Williams, A
core +2 more sources
Pharmacy, 2015 It has been reported that patients frequently discontinue treatment for erectile dysfunction (ED) with phosphodiesterase type 5 inhibitors (PDE5Is) despite apparently good therapeutic results.
Connie C. J. Louizos, Peter K. Knight
doaj +1 more source
Erectile dysfunction - an update of current practice and future strategies [PDF]
, 2013 Erectile dysfunction (ED) is defined as the inability to achieve and maintain a penile erection adequate for satisfactory sexual intercourse.1 Up to 150 million men worldwide suffer from ED and this figure is likely to double by the year 2025.2 A number
Kalsi, J, Muneer, A
core +1 more source